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Abstract
Background: Pentoxifylline (PTX) affects many processes that may contribute to the pathogenesis of severe
malaria and it has been shown to reduce the duration of coma in children with cerebral malaria. This pilot study
was performed to assess pharmacokinetics, safety and efficacy of PTX in African children with cerebral malaria.
Methods: Ten children admitted to the high dependency unit of the Kilifi District Hospital in Kenya with cerebral
malaria (Blantyre coma score of 2 or less) received quinine plus a continuous infusion of 10 mg/kg/24 hours PTX
for 72 hours. Five children were recruited as controls and received normal saline instead of PTX. Plasma samples
were taken for PTX and tumour necrosis factor (TNF) levels. Blantyre Coma Score, parasitemia, hematology and vital
signs were assessed 4 hourly.
Results: One child (20%) in the control group died, compared to four children (40%) in the PTX group. This
difference was not significant (p = 0.60). Laboratory parameters and clinical data were comparable between
groups. TNF levels were lower in children receiving PTX.
Conclusions: The small sample size does not permit definitive conclusions, but the mortality rate was
unexpectedly high in the PTX group.
Background
The mortality of severe falciparum malaria in children
admitted to African hospitals has not decreased signifi-
cantly in recent decades despite the introduction of new
anti-malarial drugs, including the rapidly acting artemi-
sinins. Disruption of the pathogenic mechanisms may
improve the outcome.
The pathogenesis of severe malaria is unclear and sev-
eral different processes may be responsible. Enhanced
production of the cytokine tumour necrosis factor
(TNF), induction of nitric oxide, cytoadherence and
sequestration, rosetting (the aggregation of parasitized
and non-parasitized red blood cells), and decreased red
blood cell (RBC) deformability are thought to contribute
to the pathogenesis of severe malaria [1,2].
Pentoxifylline (PTX), a methylxanthine, which acts as
a phosphodiesterase inhibitor, has effects on many of
these processes. It was initially developed to increase
RBC deformability and enhance blood flow in the
microvasculature. It leads to an overall improvement in
haemorheological characteristics such as RBC deform-
ability, blood viscosity, platelet aggregation, and plasma
fibrinogen concentration [3]. It may be particularly use-
ful in malaria, since it disrupts rosettes [4], prevents
neuronal cell damage [5], and reduces TNF levels [6-9].
In premature neonates with sepsis, which may share
pathogenetic processes with severe malaria, continuous
infusion of PTX decreases the mortality rate [10].
Pentoxifylline as an adjunctive therapy for severe
malaria was first proposed in the early 1990 s and to
date four clinical trials have investigated the efficacy of
the drug in severe malaria. Trials in adults have shown
conflicting results; a trial from India showed a signifi-
cant reduction in duration of coma and mortality [11],
but trials from Thailand [12] and Germany [13] showed
no effect. A study of Burundi children with cerebral
malaria also showed a significant reduction in the dura-
tion of coma [9], but the sample size was small and an
optimal dose was not established. * Correspondence: bertrand.lell@uni-tuebingen.de
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described in healthy adults [3], but little is known about
pharmacokinetics in African children with severe
malaria. The present study therefore set out to charac-
terize the pharmacokinetik porperties of PTX and to
measure its effect on pathophysiologic parameters, with
the aim to determine a dose to be tested in large multi-
centre trials.
Methods
Study area and study population
The study was approved by the Institutional Review
Boards at the Michigan State University, USA, the Inter-
national Center for Infectious Diseases Research proto-
col review committee within the National Institute of
Allergy and Infectious Diseases, U.S. National Institutes
of Health, USA and the National Ethics Committee of
Kenya. The trial was registered at ClinicalTrials.gov,
with the identifier NCT00133393.
The study was conducted between January 2002 and
September 2004, in the coastal region of Kenya, an area
of moderate to high malaria transmission [14]. Recruit-
ment was temporarily stopped for 18 months in 2002/
2003 due to patient safety concerns after the first death.
All children admitted at the Kilifi District Hospital were
eligible if they fulfilled the following inclusion criteria:
between nine months and eight years of age; cerebral
malaria (defined as peripheral parasitaemia with asexual
forms of P. falciparum; inability to localize a painful sti-
mulus (evaluated 30 minutes after correcting hypoglycae-
mia (blood glucose < 2.2 mmol/l) in patients who present
with hypoglycaemia and 30 minutes after cessation of
convulsive activity in patients who are convulsing on
admission); and informed consent given by parents or
guardians. Exclusion criteria were: mean blood pressure
(BP) < 60 mmHg (mean BP = 2/3 diastolic BP + 1/3 sys-
tolic BP); platelet count < 50/nL; spontaneous bleeding;
haematocrit < 20% or haematocrit between 20-25% with
parasitaemia > 10%; neck stiffness; or clinical evidence of
lower respiratory infections.
Study design
The study was planned as a step-wise dose-escalation con-
trolled study of ten subjects in each group, starting with
10 mg/kg, increasing by 10 mg/kg with 40 mg/kg as the
maximum dose. The first four patients were assigned to
the control group and two controls were to be added
between each dosage group. However, after preliminary
analyses, the study was stopped after 15 patients due to
patient safety concerns raised by the National Ethics Com-
mittee of Kenya and the Data and Safety and Monitoring
Board (DSMB).
Study procedures
Children were admitted to the high-dependency research
ward of the Kilifi District Hospital and were treated with a
loading dose of 15 mg/kg quinine and a maintenance
dosage of 10 mg/kg quinine every 8 hours thereafter [15].
Chloramphenicol and benzylpenicillin were administered
to all children to cover the possibility of bacterial meningi-
tis until the cultures were available. Seizures lasting longer
than 5 minutes were treated with paraldehyde, phenytoin,
or phenobarbital [16]. Mannitol was infused when evi-
dence of increased intracranial pressure was observed,
mainly retinal vein engorgement or papilledema.
Out of the 15 children recruited, 10 children received a
continuous infusion of 10 mg/kg/24 hours PTX in 0.9%
saline (5 mg PTX/mL) for 72 hours. Five children (the
first four and the last one recruited) acted as controls
and received continuous infusion of normal saline only.
On admission, demographic details of the patient, his-
tory of disease, and clinical findings (vital signs, oxygen
saturation, respiratory status, Blantyre coma score) [17]
were recorded. Laboratory on admission included para-
sitaemia, full blood count and differential white cell
count, glucose, blood culture, blood gas analysis, electro-
lytes, creatinine, lactate, and aspartate transaminase
(AST). Parasite density was counted per 100 white
blood cells or, for high parasitaemia, per 500 red blood
cells and expressed in parasites per μL.
During the study, parasitaemia, glucose, and haematocrit
were assessed 4-hourly until three consecutive slides were
negative for parasites. Vital signs were assessed quarter-
hourly during the first 4 hours and 4-hourly thereafter.
Blantyre coma score was assessed every 4 hours. A full
blood count and differential was performed at 12, 24, 48,
and 72 hours. Lactate was measured at 4, 8, 12, and
24 hours. Creatinine and AST were measured after
72 hours. Blood for determination of TNF, PTX and meta-
bolite (1-(5’-hydroxyhexyl)-3,7-dimethylxanthine) concen-
trations was taken on admission and at 1, 2, 4, 8, 12, 24,
48, and 72 hours after PTX administration. Blood was col-
lected in heparinized tubes, centrifuged to separate
plasma, and the plasma was stored frozen (-20°C) until
assayed to PTX and its major metabolite.
F o l l o w - u pv i s i t sw e r ec o n d u c t e da to n ea n dt h r e e
months after admission. During these visits, neurological
status was assessed and the examinations performed on
admission were repeated.
Laboratory methods
Plasma PTX and metabolite concentrations were deter-
mined using a validated High Performance Liquid Chro-
matographic method developed in our laboratory. Peak
drug/metabolite concentrations and the corresponding
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area under the plasma drug/metabolite concentration-
time curve was determined using the trapezoidal
method [18]. However, there were insufficient data to
allow for determination of post-infusion elimination
kinetics.
TNF levels were measured from plasma samples by
standard sandwich enzyme-linked immunosorbent assay
using pairs of cytokine specific monoclonal antibodies
according to the manufacturer’s instructions (Flexia,
Biosource International, Nivelles, Belgium) with a detec-
tion limit of 11 pg/mL. Each plate included a standard
curve of recombinant human cytokine. All specimens
were measured in duplicate and the mean value was
used in all analyses. The optical density of each well was
measured at 450 nm by a dual-wavelength plate reader
(Mikrowin, Orthvath, Germany). The correlation
between optical densities ranging from 1 to 1000 pg/ml
was strong in all cases.
Statistical analysis
Outcome variables included the number of children who
died, the number who survived with neurological seque-
lae (inability to sit or stand or walk, pick up objects, see,
hear and/or speak), and resolution time of coma, parasi-
taemia, and fever. Parasite clearance time was defined as
the time (i.e., hours after start of pentoxifylline) when
the first of two consecutive 4-hourly peripheral blood
films was negative. Coma resolution time was defined as
the time since start of PTX when a Blantyre Coma
Score of 5 was first noted. Fever clearance time was
defined as the time since start of PTX when the first of
five consecutive 4-hourly rectal temperatures was below
37.5°C. Laboratory values were compared between inter-
vention groups by flagging values outside of normal
ranges. Serious adverse events were defined as any unto-
ward medical occurrence that is life-threatening, results
in death, or in prolongation of hospitalization. Fisher’s
exact tests were used to compare categorical variables
and Wilcoxon rank sum tests and Student’s t-tests were
used to compare continuous variables.
Results
Admission characteristics of the children allocated to
the PTX and control groups were similar (Table 1).
With the exception of rectal temperature (p = 0.03),
there were no statistically significant differences among
study groups, at a significance limit of 0.05.
Outcome variables are shown in Table 2. Five children
died; 4 in the PTX group and 1 in the control group,
resulting in an overall mortality rate of 33%. Although
the mortality rate was high in the PTX group, it was not
statistically different from that of the control group.
Respiratory arrest was the cause of all deaths and signs
of raised intracranial pressure were present in each case
[19]. There were no significant differences between
study groups for any outcome variable; in particular,
coma resolution time and number of children with sei-
zures. Fever resolution time and parasite clearance time
were higher in the PTX group, but the differences were
not statistically significant.
Two children experienced a serious adverse event and
the PTX infusion was stopped as a consequence. One
child developed hypotension (mean blood pressure
below 60 mmHg), and the other demonstrated frequent
Table 1 Clinical and laboratory parameters on admission
PTX
(N = 10)
Controls
(N = 5)
Sex (Male) 3 (30%) 3 (60%)
Age (years) 3.6 ± 1.1 3.6 ± 1.9
Duration of illness (days) 2 (1 - 5) 2 (1 - 3)
Seizures before admission 8 (80%) 4 (80%)
Blantyre Coma Score 2 (0 - 2) 2 (0 - 3)
Adelaide Coma Score 6 (3 - 9) 7 (4 - 7)
Rectal temperature (°C) 38.9 ± 1.1 37.6 ± 0.8
Mean blood pressure
(mm Hg)
74 ± 15 74 ± 11
Presence of respiratory
distress
2 (20%) 1 (20%)
Parasitaemia (/μL) 40,991 (2,331 -
380,000)
29,988 (1,950 -
264,000)
Haemoglobin (g/dL) 8.2 ± 1.4 9.7 ± 1.4
Glucose (μmol/L) 7.0 ± 3.9 5.5 ± 3.8
Creatinine (μmol/L) 65 ± 27 68 ± 33
Platelets (/nL) 77 (23 - 432) 354 (69 - 730)
pH 7.341 ± 0.124 7.347 ± 0.114
Base excess (mmol/L) -4.4 (-18.2 - 13.3) -7.2 (-14.6 - 2.2)
Data are reported as N (%), mean ± standard deviation, or median (range).
Table 2 Outcome variables by treatment assignment
PTX Control p
All subjects (N = 10) (N = 5)
Serious adverse events 2 (20%) 0 (0%) 0.52
Seizures during stay 4 (40%) 4 (80%) 0.28
Deaths 4 (40%) 1 (20%) 0.60
Time to death (hours) 35 (8 - 54) 10 -
Among survivors (N = 6) (N = 4)
Parasite clearance time (hours) 43 ± 9 31 ± 8 0.05
Fever resolution time (hours) 29 ± 17 17 ± 10 0.28
Coma resolution time (hours)* 8 (4 - 36) 8 (4 - 12) 0.69
Duration of hospitalization (days) 3 (3 - 17) 4 (3 - 15) 0.52
Neurological impairment after
72 hours
1 (17%) 2 (50%) 0.50
Neurological sequelae at 3
months
0 (0%) 1 (25%) 0.40
* Restricted to subjects with no neurologic impairment at 72 hours.
Data are reported as N (%), mean ± standard deviation, or median (range).
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and gastrointestinal bleeding. The latter patient had
Salmonella sepsis on admission, required two blood
transfusions and was subsequently found to be HIV
positive. Two children in the PTX group needed trans-
f u s i o n ,c o m p a r e dt on o n ei nt h ec o n t r o lg r o u p .T h e
blood culture was positive in two subjects in the PTX
group (one Salmonella and one Staphylococcus epider-
midis), and no positives were found in the control
group.
Twelve children (80%) had haemoglobin below 8 g/dL
on at least one occasion, 2 (13%) had aspartate transa-
minase above 150 U/L at least once, and 3 (20%) had
creatinine above 100 μmol/L at least once. There was
no statistically significant difference in the number of
children with laboratory values outside of the normal
range between the control and intervention groups for
any laboratory parameter.
TNF values were consistently and significantly reduced
in the PTX group starting 2-4 hours after start of
administration (Figure 1). There was a difference
between the study groups at baseline, but not at hour 1.
The pharmacokinetic properties are summarized in
Table 3. There was considerable variation in the PTX
and metabolite pharmacokinetic parameters.
Discussion
Pentoxifylline has often been proposed as an adjunct
therapy in cerebral malaria [20-22]. This is based on the
evidence that it reduces mortality in sepsis [10], a dis-
ease that seems to share similar pathogenetic features
with severe malaria.
A study conducted in 56 Burundian children showed
that PTX (10 mg/kg/day) caused a significant reduction
in median coma resolution time, which was six hours in
the PTX group compared to 46 hours in the control
group. The reduction in mortality (17% vs. 0%) was not
statistically significant, but the sample size may have
been too small to detect such a difference. However this
was not a double blind randomized trial, and it is
unclear if the dose used was the optimal dose.
In adults, the studies of PTX in cerebral malaria are
contradictory. In a study of 52 Indian adults with cerebral
malaria, there was a significant reduction in duration of
coma, but not mortality in the PTX group [11]. In a
study of 45 adult Thais with severe malaria (18 had cere-
bral malaria), no differences were seen when PTX was
used at higher doses (20 mg/kg daily and 40 mg/kg daily)
[12]. A study performed in Germany in a heterogeneous
cohort of malaria, which included three cerebral malaria
cases, showed no effect of PTX (20 mg/kg daily) [13].
The rationale for the present study was the need to
describe pharmacokinetics in children with cerebral
malaria in order to decide on a dosage for large-scale
studies. However, we found that the efficacy of the drug
was associated with more side effects than the Burun-
dian study, despite using the same dose. The study was
not designed as an efficacy study and as a consequence
there was no randomization of the intervention and the
number of subjects was small, due to the early termina-
tion of the study. The difference between the Burundian
and this study remains unexplained, since the entry cri-
teria and regimens appear to be similar.
The study shows that PTX was effective in reducing
TNF levels, even at low PTX dosages. In the neonatal
sepsis, PTX was given at a dosage of 30 mg/kg per day,
which led to a reduction of TNF and other cytokines
compared to placebo [10]. In Thai adults, a high dose
(PTX infusion of 40 mg/kg daily) significantly decreased
TNF and IL-6 levels compared to a lower dose (20 mg/
kg daily) with significantly lower TNF-receptor plasma
concentrations after 12 and 24 hour of high-dose PTX
infusion, but there were no differences between the
groups with regard to IL-6 receptor levels [8].
The pharmacokinetic properties of PTX administered
orally are well described in adults [3]. Considerably less
information is available on the pharmacokinetics of the
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Figure 1 Tumour necrosis factor levels over time by treatment
assignment. Values are plotted as mean ± 95% confidence
intervals.
Table 3 Pharmacokinetic parameters of pentoxifylline
and its metabolite
PTX
(N = 10)
PTX metabolite
(N = 9)
Cmax (ng/mL) 151 (82 - 332) 94 (35 - 291)
Tmax (hours) 10 (2 - 24) 12 (4 - 24)
AUC0-24 (ng
. h/L) * 2828 (1743 - 3052) 1567 (831 - 1585)
AUC0-∞ (ng
. h/L) * 7641 (5123 - 9177) 2314 (852 - 2855)
* Data restricted to seven subjects with sufficient data points.
Data are median (range).
Cmax : maximum concentration; Tmax : time to maximum concentration;
AUC0-24 : area under the curve (0 to 24 hours); AUC0-∞ : area under the curve
(0 to infinity).
Lell et al. Malaria Journal 2010, 9:368
http://www.malariajournal.com/content/9/1/368
Page 4 of 6drug administered as an infusion and in children, sick or
healthy. Due to the short elimination half-life of PTX
and its metabolite, a continuous infusion is probably
required when used in cerebral malaria. The basic phar-
macokinetic parameters measured in the present study
show a considerable variation compared to plasma levels
seen during continuous infusion in healthy adults
[23,24]. All children had a severe systemic disease and
some had co-morbid conditions, such as bacteraemia.
PTX undergoes a high first-pass metabolism and liver
impairment is known to profoundly alter the pharmaco-
kinetics of PTX. However, for a drug with a high hepatic
extraction ratio, decreased hepatocellular activity would
be expected to have only a minor effect on clearance
following intravenous infusion. Thus, the observed wide
variability in pharmacokinetic parameters in this study
partly reflects the limited number of subjects for whom
complete drug concentration-time profiles were available
for analysis.
Conclusions
The use of PTX in children with cerebral malaria
remains unresolved. It reduces the TNF levels, but
whether this effect reduces mortality can only be exam-
ined by further studies in moderate malaria and a large-
scale multi-center trial.
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